Mobileye Global (MBLY) Meets Q4 Earnings Estimates

Mobileye reported adjusted EPS of $0.06 for the quarter ended December 2025, matching the Zacks consensus but down from $0.13 a year earlier, and revenue of $446 million, a ~9% year-over-year decline while beating estimates by 1.39%. Estimate-revision trends were unfavorable heading into the release, leaving Mobileye with a Zacks Rank #4 (Sell); consensus outlook is $0.08 EPS on $474.21m revenue next quarter and $0.40 on $2.0bn for the fiscal year. Given the modest beat but deteriorating estimate momentum, investor sentiment is likely to remain cautious until management color on the call clarifies near-term guidance and demand visibility.

Analysis

Market structure: Mobileye’s in-line EPS but y/y revenue decline (Q vs $490M -> $446M) signals soft near-term OEM demand or model ramp timing, benefiting diversified ADAS suppliers (Aptiv/APTV, Magna/MGA) and chip vendors with broader secular AI demand (NVDA). Losers: pure-play ADAS vendors with high revenue concentration (MBLY) face pricing pressure and estimate downgrades; Tier-1 sensor contractors see contracted order timing risk. Cross-asset: a downside repricing in MBLY should raise single-name equity vols, modestly steepen credit spreads for tech suppliers and nudge US rates slightly lower on risk-off within 48-72 hours.

Risk assessment: Tail risks include a high‑profile ADAS safety recall or regulatory limits on L2+ features, which could cut FY revenue >15% and trigger large downgrades; loss of a marquee OEM contract is another low-probability, high-impact event. Immediate (days): reaction to the earnings call; short-term (30–90 days): estimate revisions and OEM production notices; long-term (2–5 years): adoption curve of software monetization and liability regime. Hidden dependencies: OEM production cadence, sensor supply contracts, and pay-per-mile software deals that shift revenue from hardware to recurring streams. Key catalysts: management guidance, new OEM production ramps, regulatory rulings — materially positive if FY guide >$2.1B or negative if < $1.9B.

Trade implications: Direct: establish a tactical 2% portfolio short/put spread in MBLY (see options below) ahead of the call follow‑up and estimate revisions; if guidance is neutral/weak, scale to 4% within 5 trading days. Pair trade: short MBLY and long APTV (1:1 notional) to capture dispersion between a concentrated software vendor and a diversified ADAS/hardware supplier. Sector tilt: reduce concentrated auto-ADAS beta by ~1–3% and reallocate to NVDA/semiconductor exposure for secular AI demand.

Contrarian angles: The market may underweight Mobileye’s large dataset and software moat — a temporary revenue miss could be priced as structural when it’s tactical; if management reiterates multi-year recurring revenue targets, the selloff may be overdone. Consider a small, long-dated asymmetric bet (18-month call or LEAP) if post-call guidance confirms OEM ramps or software monetization with FY >$2.1B. Watch for quick reversals: a single new OEM production announcement could produce 15–30% upside, so size positions to limit blow-up risk.

Key Decisions for Investors

• Initiate a tactical bearish position on MBLY: buy a 3-month put spread (long 1 ATM put, short 1 -20% OTM put) representing ~2% of portfolio notional to limit cost, then review after the earnings call; increase to 4% if management guides FY revenue < $1.9B or cuts Q guidance below $450M.
• Execute a pair trade: short MBLY equal-notional and go long Aptiv (APTV) for 1–2% portfolio weight as a hedge to capture ADAS dispersion; close pair if MBLY improves guidance to >$2.1B or APTV shows relative operational weakness beyond -10% vs sector.
• If seeking asymmetric upside, buy an 18‑month MBLY LEAP call (strike near current price) sized at 0.5–1% portfolio for recovery/monetization thesis; exit if share price fails to recover or if recurring revenue targets are missed for two consecutive quarters.
• Reduce concentrated exposure to pure-play auto-ADAS names by 1–3% and redeploy into semiconductor/AI leaders (e.g., NVDA) for secular growth; re-evaluate allocation after 30–90 days of estimate revisions and OEM production updates.